Forget This Biotech Stock’s Rally Signals Fresh Jump
NovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
This look at Zero Based versus traditional budgeting methods shows where each excels and where it may fall short for different spending habits.
19,606 articlesNovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
eXp Realty unveils a new division to help agents break into the new construction market. The program aims to close th...
Three high-variance names—Moderna, Trade Desk, and MicroStrategy—reversed declines to rally in early March, signaling...
A little-known rival to SCHD has delivered competitive long-run gains and steady monthly income, thanks to a mid-cap ...
Tilray Brands is targeting a milestone $1.2 billion in annual revenue next year. This article digs into how the compa...
As ETF flows shift risk appetite, bitcoin’s next move increasingly depends on macro signals from oil prices, yields, ...
A rumored alliance between AMD and Meta Platforms could reshape AI hardware and software ecosystems. This article exa...
A new breed of data firms is staking its future on owning compute. This land data startup is buying GPUs and mapping ...
EWY has surged in 2026 on AI-driven demand for memory chips, attracting a growing cohort of retirees into the play. T...
When a single DeFi trade went wrong, a crypto trader faced staggering losses as slippage and liquidity gaps magnified...
A look at five 2016 IPOs shows how a $1,000 investment in each would have fared through 2026, highlighting divergent ...
FCC Chairman Brendan Carr signals a renewed push to enforce public-interest standards on TV stations, warning that li...